Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Granulomatosis with Polyangiitis and Microscopic Polyangiitis Treatment Study

Clinical Trial Title: 
A randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the safety and efficacy of two different dose regimens as add-on to standard of care in subjects with granulomatosis with polyangiitis and microscopic polyangiitis.
Clinical Trial Protocol ID: 
19010902
Clinical Trial Investigator Name: 
Joel Block, MD
Clinical Trial Protocol Description: 

The purpose of this study is to investigate the safety and efficacy of two different dose regimens as add-on to standard of care in subjects with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). A total of 36 patients will take part in this study at approximately 22 centers in the United States of America. At Rush, we expect to enroll approximately 2 participants.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are male or female, and at least 18 years of age or older.
  • Have a diagnosis of GPA or MPA.

You will be excluded from the study if any of the following criteria apply to you:

  • Have any other multisystem autoimmune disease.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Arthritis and Other Rheumatic Diseases
Contact Phone: 
(312) 563-2955
Contact Name: 
Joshlean Fair